Patrick Weiss Sells 14,730 Shares of Twist Bioscience Corp (NASDAQ:TWST) Stock

Twist Bioscience Corp (NASDAQ:TWST) SVP Patrick Weiss sold 14,730 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $30.66, for a total transaction of $451,621.80. The transaction was disclosed in a filing with the SEC, which is available at this link.

NASDAQ:TWST traded down $1.90 during midday trading on Thursday, reaching $28.79. 249,625 shares of the stock traded hands, compared to its average volume of 218,291. The company has a fifty day moving average of $29.91 and a 200 day moving average of $26.07. Twist Bioscience Corp has a 12 month low of $12.38 and a 12 month high of $35.95. The company has a debt-to-equity ratio of 0.03, a quick ratio of 6.96 and a current ratio of 7.18. The stock has a market capitalization of $987.84 million and a P/E ratio of -1.13.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.83) by ($0.09). Twist Bioscience had a negative net margin of 204.63% and a negative return on equity of 168.45%. The firm had revenue of $13.60 million for the quarter, compared to the consensus estimate of $12.51 million. On average, analysts predict that Twist Bioscience Corp will post -3.8 EPS for the current fiscal year.

A number of research firms recently commented on TWST. Zacks Investment Research lowered shares of Twist Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, May 8th. Evercore ISI began coverage on shares of Twist Bioscience in a report on Friday, May 31st. They set an “outperform” rating and a $26.66 price target for the company. Finally, ValuEngine upgraded shares of Twist Bioscience from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $26.55.

Hedge funds and other institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC purchased a new position in shares of Twist Bioscience in the second quarter worth approximately $3,216,000. Susquehanna International Group LLP purchased a new position in shares of Twist Bioscience in the second quarter worth approximately $404,000. Nuveen Asset Management LLC purchased a new position in shares of Twist Bioscience in the second quarter worth approximately $2,527,000. Morgan Stanley boosted its holdings in shares of Twist Bioscience by 28.9% in the second quarter. Morgan Stanley now owns 2,223 shares of the company’s stock worth $65,000 after buying an additional 499 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in shares of Twist Bioscience in the second quarter worth approximately $2,264,000. Institutional investors and hedge funds own 29.47% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Further Reading: What are the benefits of investing in REITs?

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.